According to the recently published recommendations, mutational screening for the TP53 gene should complement the FISH analysis for genetic risk stratification in CLL and the decisions before each therapy (Table 1) [2,20,107]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.